临床外科杂志 ›› 2025, Vol. 33 ›› Issue (8): 836-840.doi: 10.3969/j.issn.1005-6483.20241488

• 论著 • 上一篇    下一篇

血清微小核糖核酸-335-5p、内皮细胞特异性分子-1对食管癌病人的早期诊断及预后评估价值

  

  1. 237000  安徽六安,安徽省六安市人民医院肿瘤内科
  • 收稿日期:2024-09-11 修回日期:2024-09-11 出版日期:2025-08-20 发布日期:2025-08-20
  • 通讯作者: 胡传朋,Email:15055234265@163.com
  • 基金资助:
    六安市科技计划项目(20221akj042)

Value of serum miR-335-5p and ESM1 in early diagnosis and prognostic evaluation of esophageal cancer patients

  1. Department of Oncology,Lu'an People's Hospital of Anhui Province,Lu'an 237000,China
  • Received:2024-09-11 Revised:2024-09-11 Online:2025-08-20 Published:2025-08-20

摘要: 目的 探讨血清微小核糖核酸-335-5p(miR-335-5p)、内皮细胞特异性分子-1(ESM1)对食管癌病人的早期诊断及预后评估价值。方法 2019年4月~2023年4月收治的经病理学检查确诊为食管癌的81例病人为食管癌组,同期身体健康体检者81例为对照组。采用实时荧光定量聚合酶链反应(qRT-PCR)检测miR-335-5p、ESM1水平。食管癌病人根据随访结果分为预后良好组(46例)和预后不良组(35例)。Pearson相关性分析病人血清miR-335-5p、ESM1之间的关系。绘制受试者工作特征(ROC)曲线分析血清miR-335-5p、ESM1水平对食管癌的诊断价值以及评估食管癌病人预后的价值。结果 与对照组相比,食管癌组病人血清中miR-335-5p水平显著降低,ESM1水平显著升高,差异有统计学意义(P<0.05)。miR-335-5p与ESM1存在结合位点,Pearson相关性分析结果显示,食管癌病人血清miR-335-5p与ESM1水平呈负相关(r=-0.538,P<0.001)。与单独诊断相比,血清miR-335-5p、ESM1水平联合对食管癌诊断的AUC显著升高(ZmiR-335-5p~miR-335-5p+ESM1=2.625,P=0.009;ZESM1~miR-335-5p+ESM1=4.156,P<0.001)。miR-335-5p、ESM1水平与TNM分期、淋巴结转移、分化程度有关(P<0.05)。预后不良组血清miR-335-5p水平与预后良好组相比显著降低,ESM1水平显著升高,差异有统计学意义(P<0.05)。血清-miR-3355p、ESM1水平联合对食管癌病人预后评估的AUC与单独检测相比显著升高(ZmiR-335-5p~miR-335-5p+ESM1=2.128,P=0.033;ZESM1~miR-335-5p+ESM1=2.440,P=0.015)。结论 食管癌病人血清中miR3355p低表达、ESM1高表达,二者对食管癌病人的早期诊断及预后评估有一定的临床价值。

关键词: 微小核糖核酸-335-5p, 内皮细胞特异性分子-1, 食管癌, 诊断, 预后

Abstract: Objective  To investigate the value of serum micro ribonucleic acid-335-5p (miR-335-5p) and endothelial cell-specific molecule-1 (ESM1) in the early diagnosis and prognosis of patients with esophageal cancer.Methods A total of 81 patients diagnosed with esophageal cancer by pathological examination were selected from April 2019 to April 2023 as the esophageal cancer group,and 81 healthy volunteers who underwent physical examination in our hospital were selected as the control group.Real-time quantitative polymerase chain reaction (qRT-PCR) was used to detect the levels of miR-335-5p and ESM1.According to the follow-up results,46 cases were grouped into the good prognosis group and 35 cases in the poor prognosis group.Pearson correlation analysis was used to analyze the relationship between serum miR-335-5p and ESM1 in patients with esophageal cancer.Receiver operating characteristic (ROC) curve was plotted to analyze the value of serum miR-335-5p and ESM1 levels in diagnosing esophageal cancer and the value in evaluating the prognosis of esophageal cancer patients.Results Compared with the control group,the serum level of miR-335-5p in the esophageal cancer group was greatly reduced,the level of ESM1 was greatly increased (P<0.05).MiR-335-5p had binding sites with ESM1.Pearson correlation analysis showed that serum miR-335-5p was negatively correlated with ESM1 level in patients with esophageal cancer (r=-0.538,P<0.001).Compared with the individual diagnosis,the AUC of the combination of serum levels of miR-335-5p and ESM1 in the diagnosis of esophageal cancer was greatly higher (ZmiR-335-5p~miR-335-5p+ESM1=2.625,P=0.009;ZESM1~miR-335-5p+ESM1=4.156,P<0.001).The levels of miR-335-5p and ESM1 were correlated with TNM stage,lymph node metastasis and differentiation (P<0.05).Compared with the good prognosis group,the serum level of miR-335-5p in the poor prognosis group was greatly reduced,and the ESM1 level was greatly increased (P<0.05).Compared with the individual diagnosis,the AUC of combination of serum miR-335-5p and ESM1 levels in the prognostic assessment of esophageal cancer patients was greatly higher (ZmiR-335-5p~miR-335-5p+ESM1=2.128,P=0.033;ZESM1~miR-335-5p+ESM1=2.440,P=0.015).Conclusion MiR-335-5p is low expressed and ESM1 is highly expressed in the serum of esophageal cancer patients,they have certain clinical value for early diagnosis and prognostic evaluation of esophageal cancer patients.

Key words: micro ribonucleic acid-335-5p, endothelial cell specific molecule-1, esophageal cancer, diagnosis, prognosis

[1] 谢懿煊 李玉玮 许晨. 测压以及生物反馈在便秘诊断和治疗的应用[J]. 临床外科杂志, 2025, 33(8): 800-803.
[2] 黄志刚 张兴伟 张宇 邹青旭. N-乙酰转移酶10、丝氨酸羟甲基转移酶 2、YTHN6-甲基腺苷RNA结合蛋白1在肺癌组织中的表达及与临床病理特征、预后的相关性[J]. 临床外科杂志, 2025, 33(8): 827-831.
[3] 邹裕海 刘雨 梁必雄. 术前呼吸道准备与术后引流量对食管癌胸腹腔镜根治术后肺部并发症的影响[J]. 临床外科杂志, 2025, 33(8): 841-845.
[4] 张智 张青青 温艳娜 屈少磊. 食管癌根治术后并发肺部感染病人病原菌分布及血清人β-防御素-3、FMS样酪氨酸激酶3配体水平变化[J]. 临床外科杂志, 2025, 33(6): 602-606.
[5] 王伟 韩金宝 李拴玲 王丽 梁亦渊 沈秋龙 李现令 刘婷婷 王大勇 黄柳明. 儿童期胃重复畸形的临床特点及诊治[J]. 临床外科杂志, 2025, 33(5): 461-465.
[6] 贠宇辉 姬翔 韩国梁 郭伟. 食管癌胸腔镜根治术中不同喉返神经旁淋巴结清扫对近期疗效、血清髓系细胞触发受体-1、肿瘤坏死因子受体相关蛋白-1水平及生存质量的影响[J]. 临床外科杂志, 2025, 33(5): 482-485.
[7] 杨三虎 李岩 黄立军 颜振科 刘旭 李万山 姬翔. 早中期食管癌全腔镜切除术后3年无复发生存的随机森林预测研究[J]. 临床外科杂志, 2025, 33(5): 486-492.
[8] 卢海 付琴 朱允和 张先政. 咪达唑仑调节CCL2-CCR2信号通路对食管癌细胞增殖、迁移和侵袭的影响[J]. 临床外科杂志, 2025, 33(5): 493-497.
[9] 倪曲波, 吕佳豪, 陈廖斌. 腓骨肌腱滑脱症的诊治现状[J]. 临床外科杂志, 2025, 33(4): 353-356.
[10] 张晓莹, 房爱菊, 杨香山, 李静. 大汗腺分化的乳腺包裹性乳头状癌一例[J]. 临床外科杂志, 2025, 33(4): 447-448.
[11] 王怡凤 华荣 何毅. 老年食管癌病人术后并发症Clavien-Dindo分级≥Ⅲ级的影响因素及列线图预测模型构建[J]. 临床外科杂志, 2025, 33(3): 261-266.
[12] 胡迪 沈浩元. 长链非编码RNA HOTAIR在乳腺癌早期诊断中的价值和作用机制[J]. 临床外科杂志, 2025, 33(3): 329-331.
[13] 侯俊 任俊丽 梁婷婷 刘晶怡 王开元 潘澄澄 马秀芬. 乳腺恶性叶状肿瘤伴皮肤破溃血性溢液一例[J]. 临床外科杂志, 2025, 33(3): 293-294.
[14] 庄义骏 许南炜 赵劲歌 曾浩. 2024年欧洲泌尿外科学会前列腺癌指南更新荟萃与解读[J]. 临床外科杂志, 2025, 33(2): 113-117.
[15] 王雪静 黄智 曾嘉宾 周楚芸 郑博文 吕世栋 魏强. 新一代人工智能在前列腺癌临床诊断的研究进展[J]. 临床外科杂志, 2025, 33(2): 118-122.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 林伟箭;洪雪辉;许淑镇;等. 吸引器在腹腔镜胃癌根治术中的应用体会[J]. 临床外科杂志, 2016, 24(11): 824 .
[2] 刘方 凌娜佳 黎笔熙等 . 目标导向容量治疗对冠状动脉旁路移植术患者全身炎性反应和早期预后的影响[J]. 临床外科杂志, 2016, 24(4): 305 .
[3] 张华园;高峰;董军等. 颅内多发脑膜瘤一例[J]. 临床外科杂志, 2016, 24(4): 319 .
[4] 于振涛. 食管胃交界腺癌手术治疗现状[J]. 临床外科杂志, 2016, 24(7): 537 .
[5] 黄小龙 杨柳山 吴西林. 全胸腔镜肺癌切除术中转开胸原因分析[J]. 临床外科杂志, 2016, 24(9): 712 .
[6] 蔡建平;王亚东;张晓等. 结构脂肪乳与中/长链脂肪乳对胰十二指肠切除术后病人肝功能、蛋白质代谢、细胞免疫功能及临床不良反应的影响[J]. 临床外科杂志, 2017, 25(10): 781 -784 .
[7] 雷尚通. 甲状腺系膜切除术—基于解剖层面的手术技术[J]. 临床外科杂志, 2017, 25(11): 823 .
[8] 韩拓;肖栋;刘晓晨. 宫内节育器移位腹腔致部分小肠坏死病例报道一例[J]. 临床外科杂志, 2017, 25(12): 948 .
[9] 马雪中;顾晓箭. 体外冲击波碎石术仍然是上尿路结石治疗的重要角色[J]. 临床外科杂志, 2017, 25(2): 94 .
[10] 梁小波. 2016版中国局部进展期直肠癌诊疗专家共识解读[J]. 临床外科杂志, 2017, 25(4): 248 .